Hsieh Jason Chia-Hsun, Lin Hung-Chih, Huang Chi-Ya, Hsu Hsung-Ling, Wu Tyler Min-Hsien, Lee Chia-Lin, Chen Min-Chi, Wang Hung-Ming, Tseng Ching-Ping
Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Taiwan, Republic of China.
Department of Chemical and Materials Engineering, Chang Gung University, Taiwan, Republic of China.
Head Neck. 2015 Oct;37(10):1448-55. doi: 10.1002/hed.23779. Epub 2014 Jul 24.
Podoplanin (PDPN) is a prognostic factor for head and neck squamous cell carcinoma (HNSCC). However, PDPN expression in circulating tumor cells (CTCs) and its prognostic value are not clear.
The PowerMag system was used to enumerate CTCs from 53 patients with HNSCC prechemotherapy and 61 healthy donors. PDPN expression was determined by immunofluorescence staining. Results were correlated with clinicopathological parameters and clinical outcome, such as patient survival by receiver operating characteristic (ROC) and univariate and multivariate analyses.
PDPN was expressed in a subset of CTCs. Both EpCAM-positive CTC and PDPN-positive CTC counts were statistically different between the disease and nondisease groups (p < .0001) with no prognostic value. After a median follow-up of 10.5 months (range, 6.6-18.5 months), the PDPN-positive/EpCAM-positive CTC ratio >20% was a significant prognostic factor for death within 6 months (p = .011) and was correlated with poor progression-free survival (p = .016) and overall survival (p = .015).
PDPN-positive/EpCAM-positive CTC ratio is a prognostic factor and defining the ratio in patients with HNSCC might be valuable to clinical management.
血小板反应蛋白1（PDPN）是头颈部鳞状细胞癌（HNSCC）的一个预后因素。然而，PDPN在循环肿瘤细胞（CTC）中的表达及其预后价值尚不清楚。
采用PowerMag系统对53例HNSCC化疗前患者和61名健康供者的CTC进行计数。通过免疫荧光染色确定PDPN表达。结果与临床病理参数和临床结局相关，如通过受试者工作特征（ROC）曲线以及单因素和多因素分析评估患者生存率。
PDPN在一部分CTC中表达。疾病组和非疾病组之间，上皮细胞黏附分子（EpCAM）阳性CTC计数和PDPN阳性CTC计数均有统计学差异（p < 0.0001），但无预后价值。中位随访10.5个月（范围6.6 - 18.5个月）后，PDPN阳性/EpCAM阳性CTC比例>20%是6个月内死亡的显著预后因素（p = 0.011），并与无进展生存期差（p = 0.016）和总生存期差（p = 0.015）相关。
PDPN阳性/EpCAM阳性CTC比例是一个预后因素，确定HNSCC患者的该比例可能对临床管理有价值。
